Chronic Pain News and Research

RSS

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

DREAM gene found to be a genetic candidate for explaining old age dementia

In 2002, a group of scientists at the University of Toronto was able to identify a gene which they dubbed DREAM (downstream regulatory element antagonistic modulator).

19 Jan 2009

Epidurals and spinal anesthetics safer than previously reported

The largest ever prospective study [1,2] into the major complications [3] of epidurals and spinal anaesthetics published in the British Journal of Anaesthesia today (Monday 12 January 2009) concludes that previous studies have over-estimated the risks of severe complications of these procedures.

12 Jan 2009

New study examines the experiences of older people

It's debilitating, isolating and can lead to severe depression - yet pain is widely accepted as something to be expected and regarded as 'normal' in later life.

8 Jan 2009

Study shows major pain research funding decline at NIH

Federal funding for pain research is declining sharply, more than 9 percent a year since 2003, according to a new study published in The Journal of Pain.

12 Dec 2008

Risk factors for chronic disability after back injury

A wide range of factors-including variables related to health care and job characteristics-affect the risk of long-term disability for workers with back injuries, reports a study in the December 1 issue of Spine.

3 Dec 2008

Patient harm more common with patient-controlled pain medication

Intravenous patient-controlled analgesia (PCA) allows patients to control their own pain medication, but a new study published in the December 2008 issue of The Joint Commission Journal on Quality and Patient Safety shows that errors related to this practice are four times more likely to result in patient harm than errors that occur with other medications.

1 Dec 2008

Eli Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain

Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta (duloxetine HCl) for the management of chronic pain.

30 Nov 2008

Baffling chronic pain linked to rewiring of brain

Scientists peered at the brains of people with a baffling chronic pain condition and discovered something surprising.

26 Nov 2008

Discovery may lead to new therapeutic approaches for pain reduction

By manipulating the appearance of a chronically achy hand, researchers have found they could increase or decrease the pain and swelling in patients moving their symptomatic limbs.

25 Nov 2008

King Pharmaceuticals and Alpharma sign definitive merger agreement

King Pharmaceuticals, Inc. and Alpharma Inc. have announced that the two companies have signed a definitive merger agreement under which King will acquire all of the outstanding shares of Class A Common Stock of Alpharma for $37.00 per share in cash for a total equity value of approximately $1.6 billion.

24 Nov 2008

Researchers examine trends in prescription opioid use for non-cancer pain

A review of more than 4 million insured patients with private coverage and Medicaid, published in the The Journal of Pain showed that rates of opioid use did not differ widely between non-cancer pain conditions but there were higher rates of opioid use among Medicaid patients.

18 Nov 2008

Women separated from abusive partners often experience high-disability chronic pain after two years

Despite ample evidence that chronic pain is a serious problem in women with a history of abuse, little is known about the severity and patterns of chronic pain in this population.

18 Nov 2008

Pain and itch regulated by different molecular mechanisms

Historically, scientists have regarded itching as a less intense version of the body's response to pain, but researchers at Washington University School of Medicine in St. Louis have determined that pain and itch actually are regulated by different molecular mechanisms.

17 Nov 2008

TheraQuest's IND for abuse deterrent strong opioid (TQ-1015) accepted by FDA

TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using Securel, TheraQuest's proprietary abuse deterrent technology.

13 Nov 2008

Chronic pain makes many sufferers contemplate suicide

According to new research patients suffering chronic pain are more likely than others to consider suicide.

11 Nov 2008

MRI reveals relationship between depression and pain

The brains of individuals with major depressive disorder appear to react more strongly when anticipating pain and also display altered functioning of the neural network that modifies pain sensitivity, according to a report in the November issue of Archives of General Psychiatry , one of the JAMA/Archives journals.

4 Nov 2008

Titan Pharmaceuticals updates on Probuphine patent application

Titan Pharmaceuticals, Inc. today announced that it has received an Office Action from the U.S. Patent and Trademark Office (PTO) rejecting the claims in the Company's method of use patent application for the use of Probuphine in the treatment of opioid addiction and chronic pain.

31 Oct 2008

Pulsed ultrasound used to remote control brain circuits

In a twist on nontraditional uses of ultrasound, a group of neuroscientists at Arizona State University has developed pulsed ultrasound techniques that can remotely stimulate brain circuit activity.

29 Oct 2008

Teva granted FDA approval for Fentanyl transdermal system

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has granted approval for the Company's Abbreviated New Drug Application (ANDA) for Fentanyl Transdermal System, 25 mcg/hour, 50 mcg/hour, 75 mcg/hour and 100 mcg/hour, the AB-rated generic equivalent of Ortho McNeil's chronic pain treatment Duragesic. Shipment of this product has commenced.

20 Oct 2008